Summary
BACKGROUND: The number of individuals with autoimmune inflammatory rheumatic diseases (AIIRDs) treated with immunosuppressive drugs is increasing steadily. The variety of immunosuppressive drugs and, in particular, biological therapies is also rising. The immunosuppressants, as well as the AIIRD itself, increase the risk of infection in this population. Thus, preventing infections by means of vaccination is of utmost importance. New Swiss vaccination recommendations for AIIRD patients were initiated by the Swiss Federal Office of Public Health and prepared by a working group of the Federal Commission for Vaccination Issues as well as by consultation of international experts. METHODS: A literature search was performed in electronic databases (Cochrane, Medline, PubMed, Embase). In addition, unpublished literature was identified through a targeted website search of relevant organisations and international conferences dealing with vaccination, infectious diseases and rheumatology. RESULTS: Although data are scarce, the following main points were retrieved from the literature. Inactivated vaccines are safe, but their immunogenicity may be reduced in AIIRD patients, especially if they are under immunosuppressive therapy. Rituximab and abatacept appear to reduce significantly immune responses after vaccination. Live vaccines are generally contraindicated under immunosuppressive therapy owing to safety concerns. Specific exceptions, as well as time intervals for the administration of live vaccines after interruption of an immunosuppressive therapy, have been formulated in this article. CONCLUSION: More evidence regarding the immunogenicity and safety of vaccinations in AIIRD patients under various therapies is needed. Vaccination recommendations
Introduction
In Europe, an estimated 2% of the adult population suffers from an autoimmune inflammatory rheumatic disease (AIIRD) [10] . With a population of around 740 million, this amounts to approximately 15 million individuals in Europe. Patients with AIIRD are at an increased risk of infections, and vaccinations as an important means for prevention are indicated in this vulnerable population. The use of immunosuppressive drugs has increased in recent years in these patients [11] . As a result of different immunosuppressive medications the immunogenicity of vaccines may be reduced. Furthermore, the administration of live vaccines bears the potential risk of invasive infection with the attenuated vaccine strain, and should generally be avoided under immunosuppressive therapy; in most international guidelines, live vaccines are contraindicated under immunosuppressive therapy with a systemic effect [1, 2, 4, 12] . In Switzerland, vaccination recommendations for AIIRD patients were published in 2010 by the Swiss Society of Rheumatology [6] . In recent years, new disease-modifying medications, and biological agents, in particular, have been approved for the treatment of AIIRD patients. The growing experience with vaccinations under different immunosuppressive regimens allows the previous recommendations to be updated. The formulation of new recommendations was initiated by the Swiss Federal Office of Public Health (FOPH) and prepared by a working group of the Federal Commission for Vaccination Issues. The main principles were published in the bulletin of the FOPH in February 2014 [13] . Here we present the background information that forms the basis of the article published by the FOPH, as well as detailed practical recommendations. The recommendations are based on an extensive literature search. As scientific data on many aspects are still scarce, the majority of recommendations given in this article are based on clinical experience and expert opinion of a diverse group of specialists in the fields of rheumatology, immunology, infectiology, travel medicine and vaccination. Specific advice is given regarding timing of vaccinations in relation to different medications, as well as certain circumstances and approaches under which live vaccines may be considered during immunosuppressive therapy.
Methodology
These new recommendations were initiated by the Swiss Federal Office of Public Health and prepared by a working group of the Federal Commission for Vaccination Issues. This panel was composed of members with a wide breadth of specialties (immunology, infectious diseases, vaccinology, travel medicine, rheumatology). Drafts were distributed to panel members for comments and were discussed in four in-person meetings. The recommendations were reviewed by the Swiss Society of Rheumatology and by the Swiss Society for Allergology and Immunology. National and international experts in the field of vaccination recommendations in immunocompromised persons were consulted in the process and were composed of immunologists, rheumatologists, infectiologists and travel medicine experts. The GRADE approach was applied to rate the quality of evidence (QoE) as well as the strength of recommendation (SoR) [14] . Quality of evidence has four categories: "high quality", "moderate quality", "low quality" and "very low quality". When no published evidence could be found, it was stated as "grade of evidence not possible". The strength of recommendation was categorised into "strong" and "weak".
Search strategy
Published evidence was searched for in electronic databases (Cochrane, Medline, PubMed, Embase). Unpublished (grey) literature (unpublished reports, conference abstracts) was retrieved through a targeted website search of relevant organisations (including international vaccination recommendations such as recommendations by: the United States Centers for Disease Control and Prevention [1] , the European League Against Rheumatism (EULAR) [2] , the Infectious Diseases Society of America (IDSA) [3] several European countries [4] [5] [6] [7] [8] and others [9] ) and international conferences dealing with vaccination, infectious diseases and rheumatology. Additional articles were identified through reference lists of selected papers. Literature published up to 29 January 2014 was reviewed and analysed. The search terms from box 1 were used in combination. Only literature on adult AIIRD were included, with the exception of literature on live vaccine, such as measles, mumps, rubella and varicella, in which case the majority of data were available for paediatric patients. Mostly English and German articles were included. A summary of all relevant papers was produced. Only data from meta-analyses, systematic reviews, randomised trials, and observational studies were taken into account. Case reports were not included in this review with the exception of two case series on live vaccination under immunosuppression therapy and of adverse reactions to pneumococcal polysaccharide vaccine in patients with Behçet's disease by Hugle et al. [15] , which was considered to report important information. Articles were screened for information on increased risk of infection, vaccine-preventable infections, safety of vaccinations, immunogenicity of vaccination, timing of vaccination in relation to disease activity, timing of vaccination in relation to medication, effects of additional vaccine doses.
Results

Increased risk of infection
Infections are a substantial cause of morbidity and mortality in persons with autoimmune inflammatory rheumatic diseases [16] . The risk of infection may be increased by the disease itself [17] [18] [19] , but also by the use of immunosuppressive and immunomodulatory drugs [20] [21] [22] [23] [24] [25] [26] [27] 188] . In the following chapters, the term "immunosuppressive therapy" will include both "immunosuppressive" and "immunomodulatory" therapy. In patients with AIIRD, the risk of acquiring a confirmed infection can be 1.7 times higher than in the general population [28] . Not only is the risk of infection higher in AIIRD patients, but also the course of infection can be more severe [29, 30] . In particular, the risk of an infection requiring hospitalisation has been shown to be 1.8 times higher in patients with AIIRD compared with healthy persons [28] .
Increased risk of vaccine-preventable infections
Patients with AIIRD have an increased risk for influenza infection [31] [32] [33] , invasive pneumococcal disease [34, 35] , and for herpes zoster [36] [37] [38] [39] [40] . Several studies have demonstrated that the risk of tuberculosis infection is higher in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients compared to the general population [41] [42] [43] [44] [45] . Also the risk of human papillomavirus (HPV) infection [46] and the incidence of cervical dysplasia are increased in SLE patients, while clearance of the virus is decreased compared with the general population [47] . Hepatitis B reactivation can be severe and can sometimes have a high mortality in patients under immunosuppressive therapy (esp. during the tapering process [48] ). Sixteen key recommendations have been formulated (box 2) and will be elaborated in the following sections. and an association with the vaccine has not been ruled out [26, [52] [53] [54] [55] [56] [57] [58] [59] [60] . An increase of Guillain Barré syndrome was also reported in patients having received brain-derived rabies vaccine, which is not in use in Europe [61, 62] . An association between mumps/measles/rubella (MMR) vaccine and immune thrombocytopenic purpura (ITP) was also reported (around 1 case per 22,300-50,000 doses) [63] [64] [65] , although a second MMR dose was not associated with an increased risk of ITP [66, 67] . Some have also suspected vaccine adjuvants of triggering autoimmune diseases (autoimmune/inflammatory syndrome induced by adjuvants (ASIA) [68] [69] [70] ). An association has not been demonstrated to date [71] [72] [73] with the exception of AS03 adjuvanted H1N1 influenza vaccine, which has been suspected to be associated with narcolepsy in Finland, Sweden, Norway, Ireland, and the United Kingdom [74, 75] . The association was most pronounced in children.
In conclusion, few vaccines were found to be associated with autoimmune reactions and they are suspected to be linked to specific antigens. Importantly, the risk of GBS and other immune diseases is increased by infection. For example, the risk of GBS within 90 days after influenzalike illness was found to be 7-fold increased (risk ratio 7.35, 95% CI 4.36-12.38) [76] and the risk of GBS after influenza infection is 4-7 times higher than after influenza vaccination [77] .
In conclusion, it is important to consider the overall risks and benefits of vaccination, as defined by epidemiological studies. Clinicians, policy makers and those eligible for vaccination should be assured that the benefits of most vaccines greatly outweigh the risks of infection. Similarly, exacerbations of rheumatic diseases after vaccination have been extensively discussed in the literature and there are several case reports of worsening disease symptoms after vaccination. However, the majority of published data support the conclusion that immunisation with inactivated vaccines is safe and does not increase disease activity in AIIRD patients, measured by clinical and biological means [78] [79] [80] [81] [15] . No such adverse reactions were seen in patients with other autoimmune or autoinflammatory diseases receiving 23-PPV vaccine. It was postulated that the presumed auto-inflammatory mechanism underlying Behçet's disease could be responsible for the severe adverse events after pneumococcal vaccination. Owing to this potential streptococcal hypersensitivity reaction, caution is warranted when giving pneumococcal vaccination to patients with Behçet's disease.
3. The vaccination status should be assessed and documented as soon as the diagnosis of an autoimmune disease is made and immunisations should be performed whenever possible before immunosuppressive treatment is started (QoE: grade of evidence not possible, SoR: strong) Ideally, the vaccination status of the patients should be assessed and documented at the earliest time point after diagnosis, and recommended vaccinations should be administered as soon as possible. If possible, vaccines should be administered before initiation of immunosuppressive therapy. Furthermore, if live attenuated vaccines are administered, the start of immunosuppressive therapy must be delayed for at least 4 weeks. Inactivated vaccines should ideally also be given at least 4 weeks before starting high-dose systemic corticosteroids or immunosuppressive medication. There are three main reasons for assessing the vaccination status of patients with AIIRDs as soon as possible: (i) some AIIRDs per se confer an increased risk of infection and vaccinations should be updated as soon as possible after diagnosis; many patients do not immediately receive immunosuppressive treatment and thus vaccines can be administered at a time point when (ii) the immunogenicity of vaccination is not compromised by the immunosuppression and (iii) live vaccines can be safely administered.
4.
The immune response to a booster vaccine administered during immunosuppressive treatment is considered to be less affected than a primary vaccine dose (QoE: low, SoR: strong) Immunosuppressive drugs interfere with the activation and clonal expansion of T and B cells. As a result, the immune response to a primary vaccine dose can be impaired. The T and B cell immune response to a vaccine booster dose is generally better preserved as more memory B and T cells (induced by the first vaccine dose) are present [86, 87] . Thus, a booster vaccination in a person under immunosuppressive therapy will usually generate protective antibody levels, although antibody responses may be lower and protection shorter than in persons without immunosuppressive treatment. It has been shown that for a booster tetanus vaccine dose immune responses were preserved under various immunosuppressive therapies [88, 89] .
In already-treated AIIRD patients vaccines should ideally be administered when the immunosuppressive therapy is lowest (QoE: low, SoR: strong)
The immunogenicity of vaccines may be reduced by an immunosuppressive therapy. The effect can be expected to be dependent on the total taken dose. To achieve the best protection, patients under immunosuppressive therapies should be vaccinated when the dosage is lowest. Furthermore, live vaccines bear the risk of a potential replication of the attenuated virus and are thus generally contraindicated under immunosuppressive therapies. Under specific circumstances live vaccines may be administered (sections 7 and 8).
It is generally safe to administer inactivated vaccines, also to AIIRD patients under immunosuppressive treatment; the immunogenicity may be reduced (QoE: moderate, SoR: strong)
The majority of published data show that the administration of inactivated vaccines to AIIRD patients under immunosuppressive therapy is safe [16, 90] . Their administration was not associated with a higher risk of vaccine reactions, nor with a worsening or reactivation of the underlying disease (see section 1).
The immunogenicity of vaccinations during the use of nonbiological disease-modifying antirheumatic drugs (DMARDs), corticosteroids and/or biological agents has been studied in patients with rheumatoid arthritis, spondyloarthritis, connective tissue disease, and vasculitis. Data exist on the immunogenicity of seasonal influenza, pandemic influenza (H1N1), pneumococcal polysaccharide, pneumococcal conjugate, hepatitis A, hepatitis B, tetanus toxoid, Haemophilus influenzae b and human papillomavirus vaccination [91] . Most studies showed slightly reduced, but sufficient immune responses following vaccination of patients with AIIRD under therapy with corticosteroids, non-biological DMARDs (with the exception of methotrexate) and tumour necrosis factor (TNF) blockers (table 1) . However, it was shown in several studies that methotrexate blunted the response to influenza, pneumococcal vaccination, tetanus and hepatitis A vaccination [89, [92] [93] [94] [95] . A combination therapy of TNFα blocking agents and methotrexate appeared to decrease serological responses even further [92, 96, 97] . One study suggests that the immunogenicity of inactivated vaccines may be preserved when administered on the same day as infusion of the TNF inhibitor infliximab (IFX), but may be hampered when administered several weeks afterwards, when the full immunosuppressive effect has developed. This effect was observed in rheumatoid arthritis patients, but patients with ankylosing spondylitis developed good antibody responses independent of the time of vaccination in relation to IFX infusion [98] . For now, inactivated vaccinations should be applied regardless of timing of IFX, as most studies have shown sufficient immunogenicity of inactivated vaccinations under sole IFX treatment [94, [99] [100] [101] . More data will be necessary for a reliable recommendation regarding the timing of vaccination and infliximab infusions. Abatacept is a fusion protein composed of the extracellular domain of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the IgG1 Fc, which blocks the interaction between the surface molecules CD80/86 on an activated antigen-presenting cell and CD28 on T cells and inhibits T cell activation. It has been shown to reduce significantly the humoral immune response to influenza, pneumococcal and tetanus toxoid vaccination [102, 103] . In healthy subjects receiving abatacept, this effect was most severe when the vaccination was administered 2 weeks after a single dose of abatacept treatment. If vaccination was given before abatacept, the effect was minor [104] [105] [106] . In contrast, tocilizumab (a humanised monoclonal antibody that binds soluble as well as membrane-bound interleukin-6 receptors and thereby blocks the proinflammatory effects of interleukin-6) does not seem to affect the immunogenicity of influenza, pneumococcal conjugate, pneumococcal polysaccharide or tetanus vaccination [107] [108] [109] [110] [111] . Most impressively, humoral immune responses to influenza and pneumococcal vaccination were nearly absent in the 6 months after rituximab administration due to the transient loss of immunocompetent B cells [112, 113] . (Rituximab [RTX] is a chimeric monoclonal antibody directed against CD20, a molecule expressed specifically on B cells.) Also, administering rituximab in the weeks after immunisation may compromise vaccine responses. Immunogenicity seems to be partly restored 6-8 months after RTX therapy [113] . As a general rule, the immunogenicity of vaccinations may be reduced under immunosuppressive therapy. Nonetheless, vaccination of AIIRD patients under immunosuppressive treatment with inactivated vaccines is generally recommended. As vaccines may not be sufficiently immunogenic under immunosuppressive treatment, serologic testing is indicated, especially after a primary vaccination course (see section 11). Some further relevant aspects on timing of vaccination under different immunosuppressive agents can be found in section 8.
In general, live vaccines should be avoided in AIIRD patients under treatment with a systemic immunosuppressive effect (QoE: grade of evidence not possible, SoR: strong)
Scientific data on live vaccinations are scarce in AIIRD patients and are mostly available on re-vaccinations (table 2) .
In general, live vaccines should be avoided during systemic immunosuppressive therapy, but some exceptions apply (table 3 ). An individual patient approach may be necessary, taking into account the underlying disease, the medication, the replication capacity of the vaccine and the risk of infection. If a live vaccine is indicated under immunosuppressive treatment, a specialist (e.g. vaccination / travel medicine specialist / immunologist) should be consulted.
Consider replication capacity of live vaccines
The administration of live vaccines to immunodeficient patients bears the risk of replication of the attenuated vaccine micro-organism and clinically manifest infection. Several case reports on severe side effects after the administration of a live vaccine to patients under immunosuppressive treatment have been published [155, 156] . Some live vaccines (e.g. yellow fever vaccine) have a greater replication capacity than others (e.g. varicella) [157] [158] [159] [160] . When deciding on whether a person under immunosuppressive treatment can receive a live vaccine, the replication capacity, the relative risks of different live vaccines as well as the availability of an antiviral agent, immunoglobulin or antibiotic treatment must be taken into account (table 4) .
Consider risk of infection
When evaluating the administration of a live vaccine to an immunocompromised patient, the risk of exposure has to be taken into account. In Switzerland, for instance, wild type varicella, mumps, measles and rubella viruses are present, and exposure cannot be safely avoided. Contrary to this, exposure to yellow fever is a travel-associated risk, which can usually be avoided.
A vaccination / travel medicine specialist should be contacted before administration of a live vaccine
If an AIIRD patient is under immunosuppressive therapy and immunity towards measles, rubella, varicella and yellow fever is unknown (for yellow fever only if a previous vaccination was performed), specific serological tests should be performed. If the patient is not immune against measles, rubella and varicella and cannot be vaccinated owing to the immunosuppressive therapy, the vaccination fig. 1 ).
Depending on the drug, different intervals between immunosuppressive treatment and vaccination are advised (QoE: very low, SoR: weak)
Inactivated vaccines
Safety
Figure 1
Scheme for the application of a live vaccine when the extent of the pharmacological immunosuppression is unclear.
From safety aspects, inactivated vaccines can be given at any timepoint during immunosuppressive therapy.
Immunogenicity
For several medications, the timing of vaccination in relation to medication appears to have an effect on immunogenicity (see also section 6) and timing of inactivated vaccination in relation to immunosuppressive treatment should be considered (table 5) .
Live vaccines
For safety reasons, it is advisable to wait for a certain time period after cessation or interruption of an immunosuppressive agent before administrating a live vaccine. The duration of the immunosuppressive effect depends on (i) the half-life of the active drug component and (ii) recovery from the immunological effect (e.g. B and/or T cell depletion). For most immunosuppressive medications this timepoint has not been clearly defined [87] . There are some general recommendations summarised in table 6.
Recommended vaccinations
General basic vaccinations are recommended for patients with autoimmune inflammatory rheumatic diseases (QoE: moderate, SoR: strong)
Generally recommended vaccinations include immunisations against tetanus, diphtheria, polio, pertussis, hepatitis B, Haemophilus influenza b, mumps, measles, rubella and varicella. All these vaccinations are also recommended for One prospective, controlled study was performed in 10 SLE patients under treatment with prednisone ≤10 mg daily, HCQ ≤6.5 mg/kg daily, MTX ≤20 mg/ weekly, AZA ≤150 mg daily, (no other medications were allowed, incl. biological agents). All were seropositive for VZV. Vaccination was safe, but slightly less immunogenic than in control subjects [173] . AZA = azathioprine; HCQ = hydroxychloroquine; HC = healthy control; HZ = herpes zoster; IFN = interferon; IMID = immune-mediated inflammatory disease; JIA = juvenile idiopathic arthritis; JRD = juvenile rheumatic disease; MMR = mumps; measles; rubella; MTX = methotrexate; RTX = rituximab; SLE = systemic lupus erythematosus; TNF = tumour necrosis factor; TNFi = tumour necrosis factor inhibitor; VZV = varicella zoster virus; YF = yellow fever.
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AIIRD patients in accordance with general Swiss vaccination recommendations [177] .
It appears reasonable to give tetanus/diphtheria booster vaccinations every 10 years in immunocompromised persons, although this has not been studied. Regarding the live 
Oral typhoid vaccine (+) -
The replication capacity, relative risks of different live vaccines as well as the availability of an antiviral agent, immunoglobulin or antibiotic treatment must be considered when deciding on whether a person under immunosuppressive treatment can be vaccinated. * ++++ very strong systemic replication capacity, +++ strong systemic replication capacity, ++ moderate systemic replication capacity, + weak systemic replication capacity, (+) very weak systemic replication capacity † ++++ very strong risk of complication, +++ strong risk of complication, ++ moderate risk of complication, + weak risk of complication, (+) very weak risk of complication
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Swiss Med Wkly. 2015;145:w14159 vaccines mumps, measles and rubella, the general Swiss vaccination guidelines recommend the MMR vaccinations (up to two doses 1 month apart) for unvaccinated persons, or persons who were only vaccinated once and were born after 1963. Adults <40 years without a history of varicella infection should be vaccinated against varicella. In the case of a negative or uncertain history of varicella infection, specific serum antibodies can be measured [177] . MMR and varicella vaccination may not be administered to persons taking medication with an immunosuppressive effect (table 3); in these persons the respective serological tests should be performed in the case of a negative/uncertain disease or vaccination history. In immunocompromised adults exposed to an increased risk (e.g. work in kindergarten or hospital), immunity against measles and rubella should also be checked in those born before 1964, and in those ≥40 years also the immunity to varicella. Please consult sections 12, 13 and 14 for further recommendations.
Vaccinations for specific risk situations (QoE: moderate, SoR: strong)
Vaccinations against hepatitis A, meningococci, tick-borne encephalitis and specific travel vaccinations should be performed according to general Swiss vaccination recommendations [177, 178] . Also in this case, as vaccines may not be sufficiently immunogenic under immunosuppressive treatment, serological testing is indicated, especially after a primary vaccination course (see section 11). It has been shown that one dose of a monovalent hepatitis A vaccination may not provide protection in patients under therapy with methotrexate, TNF blocking agents or combination therapy with methotrexate and TNF inhibitors [92, 179] . More than one dose before departure may be required for protection against hepatitis A [92] . Specific recommendations apply to live vaccines (see sections 7, 8 and 12).
10. Specific vaccinations are recommended for AIIRD patients as they may require more comprehensive protection (QoE: moderate, SoR: strong) Owing to an increased risk of influenza and pneumococcal infections [31, 32, 34, 35] and associated complications, the pneumococcal and annual seasonal influenza vaccinations are recommended in AIIRD patients. Use of the It is generally safe to administer inactivated vaccines to patients under immunosuppressive therapy; the immunogenicity may be reduced. For most immunosuppressants, no specific time lag between interrupting the immunosuppressive agent and administration of an inactivated vaccine has to be respected. As vaccines may not be sufficiently immunogenic under immunosuppressive treatment, serological testing 4-6 weeks after vaccination may be indicated, especially after a primary vaccination course. If at all possible, for immunogenicity reasons it may be advisable to respect the same time intervals for inactivated vaccines as those recommended for live vaccines (table 6) . If these time intervals can be respected, no reduced immunogenicity has to be expected. Regarding B-cell depleting therapy, immune responses to inactivated vaccines may be insufficient when immunisation is performed within 6 months after RTX. Inactivated vaccines should therefore be given several weeks before initiating RTX, or at least 6 months afterwards. This recommendation is not made for safety reasons, but for immunogenicity reasons only. The recommendation is based upon the half-life of rituximab, on immunogenicity studies of inactivated vaccines as well as on CD19+ cell measurements under rituximab therapy [113, 176] . If a vaccine is indicated within 6 months after rituximab (e.g. influenza vaccine during the influenza season), it may be given. The immunogenicity and the duration of protection may be reduced significantly. CD19+ B cells can be measured before vaccination as the best proxy available for the quantity of B cells in the periphery. In addition, immunoglobulin levels can be measured. * For abatacept, it may be advisable to vaccinate shortly before abatacept application as immune responses have been shown to be severely reduced when vaccinations were given 2 weeks after abatacept [104] .
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13-valent pneumococcal conjugate vaccine (Prevenar ® ) once is recommended [180] . In opposition to EULAR and CDC recommendations [90, 181] , the use of the polysaccharide vaccine is no longer recommended (please see section 15 for further details). It could be demonstrated that the primary immune response to a pneumococcal conjugate vaccine in AIIRD patients under immunosuppressive therapy is similar to primary immune responses to the polysaccharide vaccine under therapy with non-biological DMARDs and TNFα blocking therapy [93] . Treatment with methotrexate or methotrexate in combination with TNFα blocking therapy appears to hamper the immune response to both conjugate and polysaccharide pneumococcal vaccines [94] [95] [96] 144] . Because of an increased risk of herpes zoster in AIIRD patients, herpes zoster vaccination is recommended in those aged >50 years. At the moment, herpes zoster vaccine is not available in Switzerland. If it becomes available, the Advisory Committee on Immunisation Practices (ACIP) recommendations may be followed [182] . Hepatitis B infections can be more severe in AIIRD patients under immunosuppressive therapy [48] and thus vaccination against hepatitis B is encouraged in this patient group. Vaccination against HPV is recommended in female patients aged 11-14 years and should especially be encouraged in patients with systemic lupus erythematosus. Vaccination can be recommended up to the age of 26 years, according to FOPH recommendations [46, 47, 177] . § Owing to the short half-life (4-6 hours) of anakinra, live vaccines might be given earlier than 3 months after cessation of the therapy. But so far, only data on the safe and immunogenic administration of a second MMR vaccination in three cases after cessation of anakinra for 5 half-lives have been reported [163] . ‡ As currently no data are available, this recommendation is based on expert opinion, the half-life of rituximab and on immunogenicity studies of inactivated vaccines. The reasoning for this recommendation is that if an inactivated vaccine is capable of inducing a humoral immune response after a certain time period after rituximab administration, the immune competence will also be sufficiently restored to be able to deal with a live vaccine.CD19+ B cells should be measured at the best proxy available for B cells in the periphery. Immunoglobulin levels should be measured and vaccinations may only be administered if they are at a normal level ** For safety reasons, live vaccines are contraindicated for at least 2 years after leflunomide therapy. But there is a specific wash-out option with inactivated carbon or cholestyramine: According to Sanofi Pasteur a schedule similar to the one recommended for pregnancies under leflunomide can be followed before administration of a live vaccine: After cessation of leflunomide therapy: "washout with 8 g cholestyramine 3 times daily over 11 days or 50 g activated carbon 4 times daily over 11 days. Independent of the washout method, the determination of the plasma level of leflunomide is necessary in two tests that are at least 14 days apart. After the first test with a plasma level below 0.02 mg/l it is necessary to wait for another 1.5 months before fertilisation is possible". In such a case, it is recommended to check the serology again 4-6 weeks after the additional vaccine dose. It has been shown that in AIIRD patients who had not responded to one H1N1 vaccine dose, better antibody titres and seroprotection rates could be achieved after a second dose [129] . Similarly, in one study, SLE patients who had not seroconverted after three doses of hepatitis B vaccine, developed positive antiHBs antibodies after a fourth vaccine dose [153] . For pertussis and mumps vaccines, it has not been possible to define a protective threshold for vaccine antibodies. Thus, serology after these vaccines is not useful to assess whether a person is protected. After the receipt of immunoglobulins, the patient should be observed for one month. In the case of signs of varicella infection, antiviral treatment (e.g. aciclovir) should be given promptly without awaiting confirmatory laboratory results [182, 184] .
Swiss Med Wkly. 2015;145:w14159 15. Always use conjugate vaccines in preference to polysaccharide vaccines (QoE: low, SoR: strong) Conjugate vaccines should be preferred to polysaccharide vaccines for several reasons: the former induce higher affinity antibodies, longer-lasting antibody responses and memory responses, and booster vaccinations induce even higher antibody levels. Contrarily, after the administration of a polysaccharide vaccine, secondary vaccination may elicit only poor immune responses owing to a lack of memory cells. The administration of a first dose of plain polysaccharide vaccine may even blunt the immune response to subsequent doses (also to a subsequent dose of a conjugate vaccine), such that the antibody levels following a second vaccination, and possibly the magnitude of clinical protection, may be lower than following a first vaccination [180, 185] . So far, there are no data on meningococcal vaccination in adult AIIRD patients. However, it can be concluded from immunological concepts [186] that the meningococcal conjugate vaccine should also be preferred over the polysaccharide vaccine.
16. Vaccination should preferentially be administered during stable disease (QoE: low, SoR: weak) Only a few studies have compared immunogenicity and safety of vaccinations between AIIRD patients with stable and unstable disease. Most vaccination studies in AIIRD patients were performed in patients with stable disease. In several studies on influenza, pandemic influenza and pneumococcal vaccine in patients with rheumatoid arthritis, spondyloarthritis, vasculitis, or connective tissue diseases, no increase in side effects or disease flares, nor decreased vaccine immunogenicity was seen when also patients with moderate or severe disease activity were included [122, 130, 131, 135, 137] . In studies on seasonal influenza, pneumococcal, tetanus toxoid and Haemophilus influenzae type b vaccines in SLE patients, and one study on hepatitis B vaccination in rheumatoid arthritis patients, the immunogenicity of the vaccines seemed to be reduced in patients with increased disease activity. This effect might also be attributed to the fact that patients with higher disease activity also received more immunosuppressive therapies [126, 140, 146, 152] . However, the numbers of patients in these studies were too small to draw a definite conclusion. Vaccination should therefore be preferentially administered during stable disease, more because of concerns of reduced immunogenicity (due to a higher level of immunosuppressive therapy) than of vaccine-induced flares in patients with active disease. This approach will also avoid the confusion of flare-ups of the underlying disease with vaccine-induced side effects.
Discussion
The recommendations for vaccination in patients with autoimmune inflammatory rheumatic diseases presented in this article have been formulated after an evaluation of the currently available data in the literature and after several rounds of consultations of experts in the fields of rheum- 
